secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001437749-24-029310
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp
--------------------------------------------------------------------------------

- Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.
- Acquired assets generate ~$100M annual revenue; OPKO retains NY/NJ and oncology/urology ($400M).
- BioReference repaid $9.7M credit facility with JPMorgan; no prepayment penalty.
- Pro forma cash increases to ~$273M; estimated gain on sale ~$122.6M.
- OPKO Chairman cites transaction as key step toward profitability and focus on core testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/0001437749-24-029310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-029310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer